Delay discounting and adjuvant endocrine therapy adherence in hormone receptor-positive breast cancer.
Jennifer E. Vaughn(The Ohio State University), Jeffrey S. Stein(Biomedical Research Institute), Chesley Ammermann(Biomedical Research Institute), Warren K. Bickel(University of Vermont), Maryam B. Lustberg(Yale Cancer Center)
Cited by 15
Related Papers
Prevention and Management of Chemotherapy-Induced Peripheral Neuropathy in Survivors of Adult Cancers: American Society of Clinical Oncology Clinical Practice Guideline
|Journal of Clinical Oncology|2014|1.2k
Prevention and Management of Chemotherapy-Induced Peripheral Neuropathy in Survivors of Adult Cancers: ASCO Guideline Update
|Journal of Clinical Oncology|2020|1.1k
Mitigating long-term and delayed adverse events associated with cancer treatment: implications for survivorship
|Nature Reviews Clinical Oncology|2023|296
Triple-negative breast cancer: promising prognostic biomarkers currently in development
|Expert Review of Anticancer Therapy|2020|236